What jaw complication requires monitoring in patients with metastatic cancer taking capivasertib who have received bisphosphonates or RANK-ligand inhibitors?

Patients with metastatic cancer who receive bisphosphonates or RANK-ligand inhibitors before or during capivasertib (Truqap) treatment should be closely monitored for signs or symptoms of osteonecrosis of the jaw.